Forget About the Pot Party Being Over: Get Rich off the Next Wave of Marijuana IPOs

Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) won’t be the last cannabis IPO to deliver amazing returns.

Canadian cannabis cultivators have been some of the hottest stocks to go public during this decade. After its initial public offering (IPO) and then listing on the NYSE, Canada’s leading cannabis cultivator Canopy Growth (TSX: WEED)(NYSE:CGC) is up by over 1,960% since debuting in April 2014 on the TSX and closing at $2.59 per share at writing.

While it’s doubtful that Canopy or any of the major cultivators can generate similar such returns in coming years, the hype surrounding cannabis stocks is far from over.

Legal cannabis demand to grow

What is undeniable, despite the naysayers, is that the legal cannabis industry is here to stay and will continue to grow at a solid clip, with analysts tipping that global sales will expand at a compound annual growth rate (CAGR) of around 24%.

That indicates there are considerable fortunes to be made, but it won’t be by cultivators, instead it will be made by those companies engaged in providing the required technology, biotech and management infrastructure as well as delivery systems.

This is becoming ever clearer even as cannabis cultivators like Canopy are struggling to operate profitably and are in the process of being acquired by established liquor, pharmaceutical and tobacco companies as they branch into the cannabis market.

Constellation Brands owns about a 40% stake in Canopy for a US$4 billion investment, and it appears that the billion-dollar liquor giant could be positioning itself to absorb Canada’s largest marijuana cultivator with co-founder and co-CEO Brue Linton stepping down.

Leading tobacco company Altria made a US$1.8 billion investment in Cronos Group  to acquire a 45% stake, as it moves to reposition itself and enter alternate markets as tobacco sales continue shrinking at a rapid clip. It’s also likely that, because the moat for cultivators is quite narrow, there will be an explosion of marijuana growers once the U.S. federal government legalizes cannabis use in one form or another.

Technology to lead the next round of IPOs

There is every sign that there will be a rush of cannabis technology IPOs in the wake of Akerna, which spiked by nearly 224% one day after listing and has since pulled back sharply as an increasingly negative outlook for the cannabis industry in the wake of Canopy’s disastrous results weighs on marijuana stocks.

One delivery system designer and manufacturer slated for an IPO in 2020 is Pax Labs which designs and manufactures vape delivery systems. Two months ago, it completed a US$420 million equity raising and was valued at US$1.7 billion. Since then it has signed definitive agreements with a range of cultivators including Aphria and Aurora Cannabis to provide cannabis extracts for its delivery systems.

Another cannabis company where there is growing speculation that it will IPO is Cannalife Capital which is focused on developing businesses developing cannabidiol (CBD) products. Earlier this year it announced it had signed a letter of intent to acquire Blue Sky Biologicals, a manufacturer of cannabinoid healthcare and pet care products.

Blue Sky has established the Golden Harvest brand and is developing a suite of pet care, cosmetic and personal care cannabinoid products for launch in Australia, China, Thailand, Japan, Canada, Mexico and the U.S. It has also established global manufacturing practice (GMP) standard pharma grade facilities in China which are producing organic cannabinoid products.

Foolish takeaway

There will be a slew of cannabis IPOs focused on technology, manufacturing and delivery systems over coming months, as the size of the global legal cannabis market becomes apparent and market opportunities are emphasized. The legalization of marijuana extracts, edibles and topicals in Canada on or before October 17, 2019 will create a massive opportunity for all business along the marijuana value chain.

While there are claims that cultivators such as Canopy are incapable of producing enough marijuana to meet existing demand, it will be the growing demand for edibles, delivery devices, medical applications and platforms for managing regulatory compliance which will offer the greatest opportunity.

Fool contributor Matt Smith has no position in any of the stocks mentioned.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

Top Canadian Stocks to Buy Right Now With $1,000

Cannara, Source Energy and CareRx just updated investors. See what $1,000 can buy in these Canadian stocks, plus the risks…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf’s Takeover Bid for Aurora Cannabis: What Investors Need to Know

Curaleaf's takeover bid for Aurora Cannabis offers a premium but brings stock, debt, and deal risks. Here’s what ACB investors…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

It's appealing directly to the Canadian company's shareholders with a cash-and-stock offer.

Read more »

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »